Mutation-targeted T cell responses in blood from patients with solid tumors prior to treatment and which evolve with clinical benefit from anti-PD-1 therapies

被引：0
|
作者：
Yuen, Benjamin [1 ]
Yin, Fangfang [2 ]
An, Duo [1 ]
Quach, Boi [1 ]
Guo, Linlin [1 ]
Tan, Joanne [2 ]
Peng, Songming [1 ]
Pan, Zheng [1 ]
Dalmas, Olivier [1 ]
Bao, Robert [1 ]
Jacoby, Kyle [1 ]
Sennino, Barbara [1 ]
Mandl, Stefanie [1 ]
Walters, Matt [2 ]
Jaen, Juan [2 ]
Franzusoff, Alex [1 ]
Yuen, Benjamin [1 ]
机构：
[1] PACT Pharma, San Francisco, CA USA
[2] Arcus Biosci, Hayward, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P65
引用
收藏
页数：2
相关论文
共 44 条
  • [21] Temsirolimus (T) in patients (pts) with solid tumors with AKT1/3 amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Behl, Deepti
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Mackler, Niklas
    Duvivier, Herbert L.
    Gold, Philip J.
    Patel, Sapna R.
    Duffy, Regan M.
    Mauro, Lauren A.
    Ahn, Eugene R.
    Bell, Maria
    Calfa, Carmen J.
    Grem, Jean L.
    Rueter, Jens
    von Mehren, Margaret
    Grantham, Gina N.
    Gregory, Abigail
    Hinshaw, Dominique C.
    Halabi, Susan
    Schilsky, Richard L.
    CANCER RESEARCH, 2024, 84 (07)
  • [22] Assessment of gene expression in peripheral blood from patients with advanced melanoma using RNA-seq before and after treatment with anti-PD-1 therapy with pembrolizumab (MK-3475)
    Ayers, Mark D.
    Nebozhyn, Michael
    Hirsch, Heather A.
    Cristescu, Razvan
    Murphy, Erin E.
    Kang, S. Peter
    Ebbinghaus, Scot W.
    McClanahan, Terrill K.
    Loboda, Andrey
    Lunceford, Jared K.
    CANCER RESEARCH, 2015, 75
  • [23] Expression of PD-1 on CD8+ T cells from the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical implications
    Zhang, Qun
    Zhu, Chaomang
    Li, Hongwei
    Xiang, Ping
    Zhao, Hao
    Jiang, Hao
    Wang, Gengming
    Zhou, Yongchun
    Yin, Hongmei
    Li, Duojie
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (07): : 7080 - 7087
  • [24] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Yau, T.
    Cosman, R.
    Aghmesheh, M.
    Moore, M.
    Chan, S. L.
    Mant, A.
    Eek, R.
    Zielinski, R.
    Li, P.
    Wang, H.
    Ma, Y.
    Tse, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1437 - S1438
  • [25] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Cosman, R.
    Moore, M.
    Eek, R.
    Mant, A.
    Zielinski, R.
    Chan, L. S.
    Ma, Y.
    Zhang, Q.
    Yau, T.
    Aghmesheh, M.
    Tse, A. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S840 - S840
  • [26] EX VIVO EFFICACY OF ADOPTIVE T CELL THERAPY USING AUTOLOGOUS CD8+T CELLS ISOLATED BY PD-1 POSITIVITY FROM PERIPHERAL BLOOD MONONUCLEAR CELLS IN SOLID TUMORS
    Lee, Sungkyu
    Moon, Yong Wha
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A197 - A197
  • [27] IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study
    Xu, Nong
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Xiong, Anwen
    Li, Wei
    He, Yayi
    Ren, Shengxiang
    Wang, Lei
    Yu, Jia
    Zhu, Jun
    Liu, Ying
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] MEDI4736, an anti-PD-L1 antibody with modified Fc domain: Preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors
    Khleif, S.
    Lutzky, J.
    Segal, N.
    Antonia, S.
    Blake-Haskins, A.
    Stewart, R.
    Robbins, P.
    Shalabi, A.
    Ibrahim, R.
    Wolchok, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S161 - S161
  • [29] Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy (vol 9, e003439, 2021)
    Bochem, J.
    Zelba, H.
    Spreuer, J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [30] Tumour mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
    Massard, C.
    Si, H.
    Zhang, Q.
    Higgs, B.
    Raja, R.
    Abdullah, S. E.
    Gupta, A.
    Li, W.
    van der Heijden, M.
    ANNALS OF ONCOLOGY, 2019, 30
12345